GraniteShares Launches 2x Leveraged ETFs for ISRG and NBIS Stocks.
PorAinvest
martes, 7 de octubre de 2025, 8:07 am ET2 min de lectura
ISRG--
Intuitive Surgical, Inc. (ISRG)
In the latest trading session, Intuitive Surgical, Inc. (ISRG) closed at $452.35, marking a +2.11% move from the previous day. This performance was ahead of the S&P 500's daily gain of 0.01% and the Dow's gain of 0.51%. However, the stock has depreciated by 2.53% over the past month, underperforming the Medical sector's gain of 4.67% and the S&P 500's gain of 4.83% [1].
The company is expected to post an EPS of $1.99 in its upcoming earnings release, indicating an 8.15% growth compared to the equivalent quarter last year. Revenue is projected to reach $2.41 billion, reflecting an 18.2% rise from the equivalent quarter last year [1]. For the entire year, the Zacks Consensus Estimates forecast earnings of $8.17 per share and revenue of $9.78 billion, indicating changes of +11.31% and +17.06%, respectively, compared to the previous year [1].
Intuitive Surgical, Inc. is currently trading with a Forward P/E ratio of 54.23, which is a premium compared to the industry average of 24.05. The PEG ratio of 3.72 also indicates that the stock is trading at a premium to the group, with the industry average PEG ratio being 2.5 [1].
Nebius Group NV (NBIS)
Nebius Group NV (NBIS) has surged over 350% year-to-date in 2025, climbing from around $14 last October to roughly $128 by early October 2025, near all-time highs [2]. The stock's high volatility (beta ~3.5) reflects the explosive growth and risk associated with the company [2].
In September, Nebius inked a 5-year, $17.4 billion AI infrastructure contract with Microsoft, triggering a one-day 44% stock jump to record levels [2]. The deal (expandable to $19.4 billion) gives Microsoft access to Nebius’s high-performance cloud and over 100,000 Nvidia GPUs, underscoring surging AI data center demand [2].
Nebius's Q2 2025 revenue was $105.1 million, up 625% year-over-year (and +106% QoQ) amid an AI computing boom [2]. Though still posting a net loss (EPS –$0.38 vs –$0.41 expected) as it reinvests in growth, analysts project explosive growth ahead – a Nasdaq analysis sees revenue hitting $4.25 billion by 2027 (a 231% CAGR), with positive EBITDA by 2026 [2].
Conclusion
The introduction of these leveraged ETFs by GraniteShares offers investors an opportunity to gain exposure to the short-term movements of ISRG and NBIS. While these ETFs can amplify gains, they also come with the risk of amplifying losses. Investors should carefully consider their risk tolerance and investment objectives before investing in these products.
References
[1] https://finance.yahoo.com/news/intuitive-surgical-inc-isrg-surpasses-215004872.html
[2] https://ts2.tech/en/nebius-groups-meteoric-rise-17b-microsoft-ai-deal-propels-stock-to-new-highs-whats-behind-the-hype/
NBIS--
GraniteShares has launched two new leveraged single-stock ETFs: GraniteShares 2x Long ISRG Daily ETF (ISUL) and GraniteShares 2x Long NBIS Daily ETF (NBIL). These ETFs provide investors with daily leveraged exposure to the stocks of Intuitive Surgical, Inc. (ISRG) and Nebius Group NV (NBIS). The funds aim to replicate the daily percentage change of the respective common stocks, offering investors a way to capitalize on short-term movements in the underlying stocks.
GraniteShares has recently introduced two new leveraged single-stock ETFs: GraniteShares 2x Long ISRG Daily ETF (ISUL) and GraniteShares 2x Long NBIS Daily ETF (NBIL). These ETFs aim to replicate the daily percentage change of the respective common stocks of Intuitive Surgical, Inc. (ISRG) and Nebius Group NV (NBIS), providing investors with a way to capitalize on short-term movements in the underlying stocks.Intuitive Surgical, Inc. (ISRG)
In the latest trading session, Intuitive Surgical, Inc. (ISRG) closed at $452.35, marking a +2.11% move from the previous day. This performance was ahead of the S&P 500's daily gain of 0.01% and the Dow's gain of 0.51%. However, the stock has depreciated by 2.53% over the past month, underperforming the Medical sector's gain of 4.67% and the S&P 500's gain of 4.83% [1].
The company is expected to post an EPS of $1.99 in its upcoming earnings release, indicating an 8.15% growth compared to the equivalent quarter last year. Revenue is projected to reach $2.41 billion, reflecting an 18.2% rise from the equivalent quarter last year [1]. For the entire year, the Zacks Consensus Estimates forecast earnings of $8.17 per share and revenue of $9.78 billion, indicating changes of +11.31% and +17.06%, respectively, compared to the previous year [1].
Intuitive Surgical, Inc. is currently trading with a Forward P/E ratio of 54.23, which is a premium compared to the industry average of 24.05. The PEG ratio of 3.72 also indicates that the stock is trading at a premium to the group, with the industry average PEG ratio being 2.5 [1].
Nebius Group NV (NBIS)
Nebius Group NV (NBIS) has surged over 350% year-to-date in 2025, climbing from around $14 last October to roughly $128 by early October 2025, near all-time highs [2]. The stock's high volatility (beta ~3.5) reflects the explosive growth and risk associated with the company [2].
In September, Nebius inked a 5-year, $17.4 billion AI infrastructure contract with Microsoft, triggering a one-day 44% stock jump to record levels [2]. The deal (expandable to $19.4 billion) gives Microsoft access to Nebius’s high-performance cloud and over 100,000 Nvidia GPUs, underscoring surging AI data center demand [2].
Nebius's Q2 2025 revenue was $105.1 million, up 625% year-over-year (and +106% QoQ) amid an AI computing boom [2]. Though still posting a net loss (EPS –$0.38 vs –$0.41 expected) as it reinvests in growth, analysts project explosive growth ahead – a Nasdaq analysis sees revenue hitting $4.25 billion by 2027 (a 231% CAGR), with positive EBITDA by 2026 [2].
Conclusion
The introduction of these leveraged ETFs by GraniteShares offers investors an opportunity to gain exposure to the short-term movements of ISRG and NBIS. While these ETFs can amplify gains, they also come with the risk of amplifying losses. Investors should carefully consider their risk tolerance and investment objectives before investing in these products.
References
[1] https://finance.yahoo.com/news/intuitive-surgical-inc-isrg-surpasses-215004872.html
[2] https://ts2.tech/en/nebius-groups-meteoric-rise-17b-microsoft-ai-deal-propels-stock-to-new-highs-whats-behind-the-hype/
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios